We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$233M
Cap. Flow %
2.56%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
26
Zimmer Biomet
ZBH
$18.6B
$96.7M 1.06%
+680,624
New +$100M
SYK icon
27
Stryker
SYK
$134B
$89M 0.98%
337,400
– –
KNTE
28
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$88.6M 0.97%
3,847,929
– –
SPRY icon
29
ARS Pharmaceuticals
SPRY
$563M
$87.2M 0.96%
8,740,887
– –
RPTX
30
DELISTED
Repare Therapeutics
RPTX
$87.2M 0.96%
3,322,488
-103,837
-3% -$3.35M
IMGN
31
DELISTED
Immunogen Inc
IMGN
$84.5M 0.93%
14,897,914
+1,961,292
+15% +$11.3M
ABCL icon
32
AbCellera Biologics
ABCL
$1.64B
$83.8M 0.92%
4,180,768
-2,042,251
-33% -$36.1M
XTNT icon
33
Xtant Medical Holdings
XTNT
$59.1M
$80.9M 0.89%
72,873,494
– –
SVA
34
DELISTED
Sinovac Biotech, Ltd
SVA
$78.4M 0.86%
2,839,500
– –
ELV icon
35
Elevance Health
ELV
$82.7B
$77.2M 0.85%
207,100
-128,600
-38% -$48.9M
JANX icon
36
Janux Therapeutics
JANX
$901M
$75M 0.82%
3,466,386
– –
DCPH
37
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$74.2M 0.82%
2,183,143
-1,114,158
-34% -$35.6M
ETNB
38
DELISTED
89bio
ETNB
$73.1M 0.8%
3,729,442
– –
PGNY icon
39
Progyny
PGNY
$2.46B
$71.1M 0.78%
1,270,045
-95,400
-7% -$5.27M
PASG icon
40
Passage Bio
PASG
$14.9M
$69.3M 0.76%
348,145
– –
CRSP icon
41
CRISPR Therapeutics
CRSP
$4.66B
$68.6M 0.75%
612,700
+93,700
+18% +$11.8M
KROS icon
42
Keros Therapeutics
KROS
$198M
$66.4M 0.73%
1,679,417
– –
BIIB icon
43
Biogen
BIIB
$31.8B
$66.3M 0.73%
234,200
+166,800
+247% +$54.7M
NPCE icon
44
Neuropace
NPCE
$490M
$63.6M 0.7%
4,012,281
– –
CRNX icon
45
Crinetics Pharmaceuticals
CRNX
$8.88B
$63.1M 0.69%
2,996,876
– –
TMO icon
46
Thermo Fisher Scientific
TMO
$215B
$63M 0.69%
110,300
– –
ACET icon
47
Adicet Bio
ACET
$76.6M
$56.7M 0.62%
452,054
– –
OSH
48
DELISTED
Oak Street Health, Inc.
OSH
$56.5M 0.62%
1,328,300
– –
MGTX icon
49
MeiraGTx Holdings
MGTX
$1.08B
$54.1M 0.59%
4,102,925
– –
ORIC icon
50
Oric Pharmaceuticals
ORIC
$1.16B
$48.9M 0.54%
2,337,574
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.